Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog

Int J Hematol. 1999 Jan;69(1):24-6.


Although vitamin K2 is an inducer of the in vitro differentiation of myeloid leukemic cell lines, its clinical efficacy in the treatment of myelodysplastic syndrome (MDS) is unclear. We administered a vitamin K2 analog, menatetrenone, at 45 mg daily to an 80-year-old woman with MDS (refractory anemia) heavily dependent on red-cell transfusions. The patient's pancytopenia gradually improved, and she became transfusion-independent after 14 months. Pancytopenia recurred when menatetrenone was discontinued but recovered again with readministration. Administration of menatetrenone at a dose effective in improving osteoporosis may also be useful in restoring hematopoiesis in MDS patients, possibly by way of inducing differentiation.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anemia, Refractory / complications
  • Anemia, Refractory / drug therapy*
  • Apoptosis / drug effects
  • Calcifediol / therapeutic use
  • Cell Differentiation / drug effects
  • Drug Therapy, Combination
  • Female
  • Humans
  • Osteoporosis, Postmenopausal / complications
  • Osteoporosis, Postmenopausal / drug therapy
  • Vitamin K / analogs & derivatives*
  • Vitamin K / pharmacology
  • Vitamin K / therapeutic use
  • Vitamin K 2 / analogs & derivatives


  • Vitamin K 2
  • Vitamin K
  • menatetrenone
  • Calcifediol